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Abstract 
Background: Natural products have increasingly attracted much attention as a valuable resource for the develop‑
ment of anticancer medicines due to the structural novelty and good bioavailability. This necessitates a comprehen‑
sive database for the natural products and the fractional extracts whose anticancer activities have been verified.
Description: NPCARE (http://silver.sejong.ac.kr/npcare) is a publicly accessible online database of natural products 
and fractional extracts for cancer regulation. At NPCARE, one can explore 6578 natural compounds and 2566 frac‑
tional extracts isolated from 1952 distinct biological species including plants, marine organisms, fungi, and bacteria 
whose anticancer activities were validated with 1107 cell lines for 34 cancer types. Each entry in NPCARE is annotated 
with the cancer type, genus and species names of the biological resource, the cell line used for demonstrating the 
anticancer activity, PubChem ID, and a wealth of information about the target gene or protein. Besides the augmenta‑
tion of plant entries up to 743 genus and 197 families, NPCARE is further enriched with the natural products and the 
fractional extracts of diverse non‑traditional biological resources.
Conclusions: NPCARE is anticipated to serve as a dominant gateway for the discovery of new anticancer medicines 
due to the inclusion of a large number of the fractional extracts as well as the natural compounds isolated from a 
variety of biological resources.
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Background
Although a great deal of efforts has been devoted to the 
development of therapeutics for a long time, cancer rep-
resents the major reasons for human death at an increas-
ing pace. Because the discovery of anticancer medicine 
lags behind the rapid increase in the pathogenesis of can-
cer, more than 10 million people are expected to die of 
cancer in 2020, which corresponds to approximately 20% 
of all human deaths. The difficulty in the development 
of anticancer medicines is well reflected in the fact that 
only 5% of the candidates entering clinical trials reach the 
approval for marketing [1]. To promote the discovery of 
anticancer medicines, it is necessary to enrich the chemi-
cal and biological resources from which one can select a 
promising molecular scaffold as the starting point of the 
development.
With respect to the lead discovery, it is worth not-
ing that natural products and their direct derivatives 
occupy 34% of new drugs approved over a few decades 
by US Food and Drug Administration (FDA) [2]. Besides 
the possession of unique pharmacophores and a high 
degree of stereochemistry, natural products are supe-
rior to the synthetic compounds in terms of the delivery 
to the intracellular site of action because most of them 
belong to the biologically active metabolites that should 
be the actual substrates of membrane transport systems 
[3]. Furthermore, natural products tend to have the bet-
ter bioavailability than the synthetic compounds, which 
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prevents them from being the false positives in the early 
stage of discovery [4].
Accordingly, several online databases for natural prod-
ucts have been constructed to provide a systematic and 
versatile platform for drug discovery including Super-
Natural [5], CancerResource [6], NPACT [7], TCMSP [8], 
CancerHSP [9], TCMID [10], and Phytochemica [11]. In 
addition to three dimensional structures of commercially 
available natural products and the interactions with the 
target proteins, these databases contain the pharmaco-
logical properties associated with absorption, distribu-
tion, metabolism, excretion, and toxicity (ADMET) as 
well as in vitro and in vivo anticancer activities. Despite 
the prevalence of publicly available databases, the num-
ber of the collected natural products with anticancer 
activity ranges from 1000 to 4000, which would be insuf-
ficient to serve as a breakthrough chemical library for 
lead generation. Furthermore, information is missing 
or very limited about the extract mixtures in the exist-
ing natural product databases although the traditional 
Chinese medicines have been very useful for finding the 
promising leads with respect to various pharmacological 
targets [12–14].
To provide information for a sufficient number of the 
natural products and the extract mixtures with antican-
cer activity to research communities worldwide through 
Open Access protocol, we construct an online database 
referred to as Natural Products for Cancer Regulation 
(NPCARE, http://silver.sejong.ac.kr/npcare). More spe-
cifically, NPCARE aims to complement and augment the 
public data repositories by the enrichment of the natu-
ral products and the fractional extracts isolated not only 
from plants but also from diverse non-traditional bio-
logical resources including marine organisms, fungi, and 
bacteria. NPCARE is therefore likely to serve as a com-
prehensive public resource from which users can select 
a good starting point for the discovery of anticancer 
medicines.
Data collection and assembly
The overall strategy for constructing the NPCARE database 
is depicted in Fig.  1. To obtain an extensive repertoire of 
natural products and extract mixtures, numerous biological 
data had to be manually compiled from the literature and 
web resources. This began with the searches of PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) with genus and 
species names of plants, marine organisms, fungi, and bac-
teria that contained the natural products and/or the extract 
mixtures with anticancer activity. A total of approximately 
20,000 articles were retrieved from 150 scientific jour-
nals pertaining to natural products, cancer, and medicinal 
chemistry. The journals that made a significant contribu-
tion to constructing the NPCARE database include Journal 
of Natural Product, Phytomedicine, Planta Medica, Natu-
ral Product Reports, Journal of Ethnopharmacology, Cancer 
Research, Anticancer Research, British Journal of Cancer, 
Carcinogenesis, Cancer Letters, and Biological and Phar-
maceutical Bulletin. All the retrieved scientific papers 
were inspected to obtain and catalogue the major contents 
of database such as compound names, extracts, cell lines 
used for cytotoxicity assays, cancer types, and target gene 
or protein. With respect to the data mining, multiple genus 
and species names were unified according to the taxonomy 
database provided by NCBI (https://www.ncbi.nlm.nih.
gov/taxonomy). We referred to PubChem and the original 
articles for nomenclature and stereochemistry of all the 
compounds in NPCARE. The data collected from all the 
resources were then merged to construct a non-redundant 
library containing a total of 6578 unique natural products 
and 2566 fractional extracts. Although the vast majority 
of natural products and extracts originated from eudicots 
and monocots, good anticancer agents could also be found 
from some marine organisms such as sponges and corals as 
well as from ascomycetes, basidiomycota, and bacteria. The 
list of all genus and species names is provided in Additional 
file 1.
Whenever the natural product or the extract mixture 
was found in the resources, we monitored the cell line 
used for validating the anticancer activity with respect 
to the cancer types classified by international classifica-
tion of disease (ICD) of version 10. For each cancer type, 
the subtypes determined by histological classifications 
were also specified as exemplified by squamous cell lung 
cancer, big cell lung cancer, and adenocarcinoma for 
lung cancer. Two criteria were applied separately to con-
firm the presence of anticancer activity. First, the natu-
ral products and the fractional extracts were adopted as 
the element of NPCARE if they could inhibit the growth 
of cancer cell line. Each cell line used to assess the anti-
cancer activity was hyperlinked to American type culture 
collection (ATCC) or National Center for Biotechnology 
Fig. 1 Schematic depiction of the overall strategy for constructing 
the NPCARE database
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Information (NCBI) for further information. The anti-
cancer activity of a natural product and fractional extract 
was also assessed by the capability to downregulate the 
expressions of oncogenes or to upregulate the cancer-
suppressing genes, which were implicated with the 
change in mRNA transcription levels. In this case, the 
gene names were also hyperlinked to the web pages of 
HUGO gene nomenclature committee (HGNC), Ensembl 
genome browser, UniProt knowledgebase, and catalogue 
of somatic mutations in cancer (COSMIC) so that users 
can refer to the details of the target gene. NPCARE also 
offers the hyperlink to PubChem for further information 
about the physicochemical and pharmacological proper-
ties of the natural compounds whose anticancer activities 
were verified.
Contents and data retrieval
Both natural products and fractional extracts reveal a 
wide-spectrum distribution with respect to the biological 
resources and the cancer types. The NPCARE informa-
tion table for a natural product includes the caner type, 
the scientific names of the resource organism, the com-
pound name, PubChem ID, the names of the target gene 
or protein, UniProt ID of the target gene, the biological 
function of the target protein, COSMIC and Ensembl 
ID’s of the target gene, the pattern for the target gene 
regulation, and the cell line used for measuring the anti-
cancer activity. The same is true of a total of 2566 extract 
mixtures. For each entry of NPCARE, also hyperlinked is 
the original scientific paper or the open resource at which 
the anticancer activity was reported. Users can download 
the entire database file by simply clicking “NPCARE CSV 
Download” tab in the “Useful Links” menu at NPCARE 
website.
At present, NPCARE covers 532 cell lines for 34 cancer 
types. Figure 2 illustrates the distribution of the cell lines 
with respect to the cancer types. More than 70 kinds of 
cell lines are collected in NPCARE for popular and lethal 
cancers such as non-small cell lung cancer, breast and 
colorectal cancers, and melanoma while only a few are 
available for rare cancers including Ehrlich ascites car-
cinoma, Hodgkin lymphoma, and retinoblastoma. For a 
specific cancer type, users can retrieve the list of natural 
products and fractional extracts whose anticancer activi-
ties were validated with varying cancer cell lines.
As can be seen in Fig.  3, the natural products in 
NPCARE are distributed among the diverse molecular 
targets including 58 classes of proteins that have served 
as the receptor models in the development of anticancer 
medicines. In particular, more than 500 natural prod-
ucts appear to be capable of modulating the activities 
of kinases, transcription factors, and cysteine caspases, 
which are responsible for the pathogenesis of human 
cancers by affecting the cellular signal transduction, the 
expression of oncogenes, and apoptosis, respectively. 
A large number of natural anticancer compounds in 
NPCARE are also associated with BH3 domain of Bcl-2 
family, various proteins regulating the cell cycle and apop-
tosis, and cyclin-dependent kinase inhibitors. It is also 
worth noting that NPCARE contains 171 natural prod-
ucts acting on metalloproteins including metallopepti-
dases. This would be the merit of NPCARE in the context 
that it is difficult to design a molecule that can bind tightly 
to metalloproteins due to the difficulty in finding a suit-
able chemical moiety to coordinate the central metal ion 
cofactor [15]. Furthermore, most metal-binding groups 
have poor physicochemical properties as a drug candi-
date because they have inevitably to contain a highly polar 
moiety to coordinate the positively charged metal ion. The 
natural products that modulate the expression of a metal-
loprotein target can therefore be good alternative for the 
drug candidates binding in its active site.
To evaluate the natural products in NPCARE as a 
potential drug candidate, we analyzed their physico-
chemical properties associated with ADMET: molecular 
weight (MW), calculated partition coefficient (cLogP), 
numbers of hydrogen bond acceptors (HBA) and donors 
(HBD), and number of rotatable bonds. As shown in 
Fig.  4, MWs of the natural products in NPCARE fol-
lows a Poisson-like distribution and peak in the range 
of 300–400 amu whereas the statistics of cLogP values 
exhibit a Gaussian-like distribution at the maximum 
around 2.5. The majority of natural products in NPCARE 
have HBD and HBA atoms in the ranges of 0–5 and 2–8, 
respectively, as similar to the drug molecules in the mar-
ket. Because the number of rotatable bonds falls within 
10 in the majority of NPCARE compounds (Fig. 4d), they 
would be capable of binding to the biomolecular targets 
without a significant loss of entropy. Overall, 57.4% of 
the natural products in NPCARE satisfy all the Lipinski’s 
rules for drug-likeness [16].
Judging from the good physicochemical properties, 
NPCARE molecules are expected to enrich the chemi-
cal library from which a good lead compound for anti-
cancer medicine can be identified with virtual screening. 
Because the natural products account for a large portion 
of the approved drugs [17], they have often served as the 
structural core to optimize the pharmacological activity 
within a series of similar compounds. Future updates of 
NPCARE will be focused on the increase in the number 
of natural products and simultaneously on the addition 
of the force field parameters for each natural product to 
facilitate the virtual screening of the potential inhibitors 
of various target proteins.
Also collected in NPCARE are 2566 fractional mix-
tures isolated from 1952 distinct species including 
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plants, marine organisms, fungi, and bacteria. Now the 
fractional extracts with anticancer activity are available 
for 31 cancer types. Figure 5 shows the number of bio-
logical species producing the fractional extracts with 
anticancer activity. This number distribution appears 
to be similar to that of the cancer cell lines among 
the cancer types (Fig.  2) in that the occurrences are 
high and low for prevalent and rare cancers, respec-
tively. In order to show the potential ingredients of the 
extract mixture of interest, NPCARE allows for users 
to retrieve the list of the natural products contained in 
each resource organism according to its genus and spe-
cies names.
The data in NPCARE can be readily accessed using the 
several options. As shown in Fig. 6, users can search the 
natural anticancer compounds and extracts according 
to the cancer type, the target gene or protein, and the 
taxonomic names of the resource organism. The search 
results will appear at the end of web page in the tabu-
lated form. Each entry contains the compound name, 
Fig. 2 Number distribution of the cell lines in NPCARE with respect to various cancer types and subtypes
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PubChem ID, detailed information about the target gene 
or protein, and the cell line used to measure the antican-
cer activity. Some data are hyperlinked to various exter-
nal databases and web resources including PubChem, 
UniProtKB, ExPASy, HGNC, COSMIC, Ensembl, ATCC, 
and NCBI at which further information is available for 
the natural product of interest, the target gene or protein, 
and the cell line.
Fig. 3 Distribution of the natural products in NPCARE with respect to the target proteins responsible for the pathogenesis of cancer
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The result table lists not only the natural products but 
also the fractional extracts. The potential components of 
each fractional extract are displayed by clicking on ‘Get 
Genus Compounds List’ or ‘Get Species Compounds 
List’ tabs after selecting the genus and/or species names 
of the resource organism. All or some of the ingredients 
in the extract mixture may be responsible for the anti-
cancer activity in the additive or synergistic fashions. 
Because the extract mixtures usually contain a number 
of the unknown secondary metabolites, they may offer 
a good opportunity to identify the novel candidate for 
anticancer medicine as exemplified in the discovery of 
chlorofusin by screening the microbial extracts to find 
the inhibitors of the p53–MDM2 interaction [18]. The 
unique structural scaffolds of natural products can make 
it possible to construct a chemical library that retains 
the highly relevant three-dimensional aspects in cycli-
zation and chirality. These structural peculiarities have 
the advantage of offering the selectivity in binding to the 
biomolecular target and thereby reducing the potential 
side effects.
Most drugs of natural origin in the clinical market 
stem from the plants with approximately 60% of them 
being clustered into only 10 taxonomic families [19]. 
However, the number of plant families is extended to 197 
(743 types of genus) in NPCARE, which would be bene-
ficial to users who are seeking the new candidates for the 
natural anticancer medicine. Furthermore, the contents 
of NPCARE are augmented with the natural products 
and the fractional extracts isolated from the non-tra-
ditional biological resources including 164, 120, and 48 
species of marine organisms, fungi, and bacteria, respec-
tively. The inclusion of such non-traditional resources 
seems to be necessary because they proved to contain 
a variety of natural products that developed into a new 
anticancer medicine [20, 21]. Judging from the enrich-
ment of the natural products and the fractional extracts 
isolated from a variety of plants and non-traditional 
Fig. 4 Distributions of a molecular weight, b cLogP, c numbers of hydrogen bond donors and acceptors, and d number of rotatable bonds in the 
natural products of NPCARE
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biological resources, NPCARE is anticipated to serve 
as a useful platform for the discovery of the new natural 
anticancer medicines.
Conclusion
The construction of NPCARE database aims to promote 
the development of anticancer medicines from the natural 
resources. Each natural product entry seems to serve as a 
molecular scaffold using which the anticancer activity can 
be optimized by quantitative structure–activity relation-
ship analysis. Users would also be able to identify the new 
starting points for the development of natural anticancer 
medicine by exploring the potential components of the 
fractional extracts with anticancer activity. Besides the 
augmentation of the traditional plant resources, NPCARE 
is further enriched with the natural products and the 
fractional extracts isolated from a variety of non-tradi-
tional biological resources. As a consequence, NPCARE 
contains 6578 natural compounds and 2566 fractional 
extracts isolated from 1952 biological resources including 
plants, marine organisms, fungi, and bacteria whose anti-
cancer activities have been validated with 1107 cell lines 
for 34 cancer types. It is also allowed for users to construct 
a chemical library of the natural products specific for a 
Fig. 5 Number distribution of the biological species to produce the fractional extracts with the anticancer activity for individual cancer types
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cancer type as well as for a target gene or protein. Judg-
ing from the considerable amount of entries with respect 
to diverse resource organisms, NPCARE is anticipated to 
serve as a comprehensive computational platform for the 
discovery of new anticancer medicines.
Additional file
Additional file 1. The list of genus and species names contained in 
NPCARE.
Fig. 6 Schematic workflow of NPCARE for the input query with the cancer type, the target gene or protein, and the taxonomic names of the 
resource organism
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